GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » ROE %
中文

Lifecore Biomedical (Lifecore Biomedical) ROE %

: -949.29% (As of May. 2023)
View and export this data going back to 1996. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Lifecore Biomedical's annualized net income for the quarter that ended in May. 2023 was $-142.3 Mil. Lifecore Biomedical's average Total Stockholders Equity over the quarter that ended in May. 2023 was $15.0 Mil. Therefore, Lifecore Biomedical's annualized ROE % for the quarter that ended in May. 2023 was -949.29%.

The historical rank and industry rank for Lifecore Biomedical's ROE % or its related term are showing as below:

LFCR' s ROE % Range Over the Past 10 Years
Min: -238.21   Med: -2.64   Max: 10.36
Current: -172.33

During the past 13 years, Lifecore Biomedical's highest ROE % was 10.36%. The lowest was -238.21%. And the median was -2.64%.

LFCR's ROE % is ranked worse than
94.3% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.42 vs LFCR: -172.33

Lifecore Biomedical ROE % Historical Data

The historical data trend for Lifecore Biomedical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 -15.24 -14.89 -80.32 -238.21

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -191.81 -49.16 -58.22 -296.69 -949.29

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical ROE % Distribution

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's ROE % distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's ROE % falls into.



Lifecore Biomedical ROE % Calculation

Lifecore Biomedical's annualized ROE % for the fiscal year that ended in May. 2023 is calculated as

ROE %=Net Income (A: May. 2023 )/( (Total Stockholders Equity (A: May. 2022 )+Total Stockholders Equity (A: May. 2023 ))/ count )
=-99.563/( (87.823+-4.23)/ 2 )
=-99.563/41.7965
=-238.21 %

Lifecore Biomedical's annualized ROE % for the quarter that ended in May. 2023 is calculated as

ROE %=Net Income (Q: May. 2023 )/( (Total Stockholders Equity (Q: Feb. 2023 )+Total Stockholders Equity (Q: May. 2023 ))/ count )
=-142.284/( (34.207+-4.23)/ 2 )
=-142.284/14.9885
=-949.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (May. 2023) net income data. ROE % is displayed in the 30-year financial page.


Lifecore Biomedical  (NAS:LFCR) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: May. 2023 )
=Net Income/Total Stockholders Equity
=-142.284/14.9885
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-142.284 / 102.084)*(102.084 / 244.849)*(244.849 / 14.9885)
=Net Margin %*Asset Turnover*Equity Multiplier
=-139.38 %*0.4169*16.3358
=ROA %*Equity Multiplier
=-58.11 %*16.3358
=-949.29 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: May. 2023 )
=Net Income/Total Stockholders Equity
=-142.284/14.9885
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-142.284 / -117.172) * (-117.172 / -7.844) * (-7.844 / 102.084) * (102.084 / 244.849) * (244.849 / 14.9885)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.2143 * 14.9378 * -7.68 % * 0.4169 * 16.3358
=-949.29 %

Note: The net income data used here is four times the quarterly (May. 2023) net income data. The Revenue data used here is four times the quarterly (May. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Lifecore Biomedical ROE % Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318